In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment until illness progression or even the participants are unable to tolerate the study drugs. - "Our study exposed the critical function of your KLF16/MYC regulatory axis in https://herbertt999fqa1.wikibriefing.com/user